News

The new Irvine facility is the second powder manufacturing facility, which is expected to support and strengthen risk management program, providing an internal back-up supplier for the customers.

The transaction was completed substantially under the original terms, according to which Church & Dwight paid $650m in cash at closing. The purchase price was financed with $400m

Astellas will continue development and commercialization of ASP015K in Japan. ASP015K, an oral, small molecule Janus Kinase inhibitor, is at present in Phase 2b development as a once-daily

The collaboration will leverage proprietary stem cell lines developed by Medistem to screen monoclonal antibodies for therapeutic activity in the area of regenerative medicine. Medistem CEO Thomas Ichim

Ustekinumab demonstrated effectiveness and was tolerated in patients inadequately responsive to methotrexate, and improved quality of life outcomes in patients transitioned from methotrexate in the 52-week TRANSIT study.

Vortioxetine is under investigation as an antidepressant with multimodal activity that is thought to work through receptor activity modulation and reuptake inhibition. Takeda Global Research & Development Center

Regeneron chief scientific officer and Regeneron Laboratories president George Yancopoulos said the approval of Eylea in Japan presents new treatment option for wet AMD patients and physicians. "We

The integrated chemistry data will run on Roche’s infrastructure and inside the Roche firewall to provide high performance and security. With the integration, Roche researchers’ will be able

BASF Nutrition & Health division president Walter Dissinger was quoted by Daily Record as saying that by moving the headquarters of company’s global business unit to the US,